HIV spike among B.C. drug users associated with COVID-19-related service closures, research says

Study published Friday shows that virus spiked as people had less access to services in early 2020

A new study says reduced access to HIV services amid early COVID-19 closures in British Columbia was associated with a “sharp increase” in HIV transmission among some drug users.

The study by University of British Columbia researchers says that while reduced social interaction from March to May 2020 worked to reduce HIV transmission, that may not have “outweighed” the increase caused by reduced access to services.

The study, published in Lancet Regional Health, found that fewer people started HIV antiretroviral therapy or undertook viral load testing while services were shuttered, while visits to overdose prevention services and safe consumption sites also decreased. It used data that stretched from 1996 to 2021, and included thousands of samples.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below